Results 61 to 70 of about 51,089 (251)

Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA‐HCM

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Aficamten, a novel cardiac myosin inhibitor, reversibly reduces cardiac hypercontractility in obstructive hypertrophic cardiomyopathy. We present a prespecified analysis of the pharmacokinetics, pharmacodynamics, and safety of aficamten in ...
Caroline J. Coats, Ahmad Masri, Michael E. Nassif, Roberto Barriales‐Villa, Michael Arad, Nuno Cardim, Lubna Choudhury, Brian Claggett, Hans‐Dirk Düngen, Pablo Garcia‐Pavia, Albert A. Hagège, James L. Januzzi, Matthew M. Y. Lee, Gregory D. Lewis, Chang‐Sheng Ma, Martin S. Maron, Zi Michael Miao, Michelle Michels, Iacopo Olivotto, Artur Oreziak, Anjali T. Owens, John A. Spertus, Scott D. Solomon, Jacob Tfelt‐Hansen, Marion van Sinttruije, Josef Veselka, Hugh Watkins, Daniel L. Jacoby, Polina German, Stephen B. Heitner, Stuart Kupfer, Justin D. Lutz, Fady I. Malik, Lisa Meng, Amy Wohltman, Theodore P. Abraham   +35 more
doaj   +1 more source

Alcohol septal ablation in hypertrophic cardiomyopathy: For which patients?

ESC Heart Failure, 2023
Percutaneous and surgical therapies for septal reduction for hypertrophic cardiomyopathy have been going head‐to‐head for the past 20 years with similar outcomes and mortality rates, although contemporary myectomy seems to materialize its superiority ...
Alexandru Achim, Adela Mihaela Serban, Stefan Dan Cezar Mot, Gregor Leibundgut, Madalin Marc, Ulrich Sigwart   +5 more
doaj   +1 more source

Cardiac myosin inhibitors in hypertrophic cardiomyopathy

Journal of Cardiovascular Imaging
Abstract Mavacamten, the first selective and reversible cardiac myosin inhibitor (CMI), has been introduced to the clinical arena for the treatment of obstructive hypertrophic cardiomyopathy (HCM). By reducing excessive actin-myosin cross-bridging, this agent decreases myocardial contractility and alleviates the dynamic left ventricular ...
Lim, Jaehyun, Kim, Hyung-Kwan
openaire   +1 more source

A New Chapter in the Management of Hypertrophic Cardiomyopathy: Cardiac Myosin Inhibitors

Cardiologia Hungarica, 2023
In the recent years, there has been a significant breakthrough in the treatment of hypertrophic cardiomyopathy. New precision molecules have been developed and successfully applied in clinical trials. A new class of orally available allosteric inhibitors reduces heart muscle hypercontractility, the core molecular defect of the disease, by selectively ...
Pálinkás, Eszter Dalma, Sepp, Róbert, Olivotto, Iacopo   +2 more
openaire   +2 more sources

Size‐Modulated Mesoderm‐Endoderm Divergence and Myocardial Cavitation in Micropatterned Cardioids

Advanced Science, EarlyView.
Micropatterned cardioids, CRISPR‐engineered reporter hiPSCs, deep‐tissue imaging, and single‐cell RNA sequencing are integrated to model mesoderm‐endoderm co‐development. Heart‐foregut crosstalk promotes single large cavitation inside cardioids, resembling early heart chamber formation. ABSTRACT The human heart, originating from the splanchnic mesoderm,
Plansky Hoang, David W. McKellar, Andrew Kowalczewski, Nhu Y. Mai, Meng Chai, Xiaojun L. Lian, Yi Zheng, Jeffrey Amack, Nathan Tucker, Iwijn De Vlaminck, Huaxiao Yang, Benjamin D. Cosgrove, Zhen Ma   +12 more
wiley   +1 more source

心筋細胞興奮収縮連関におよぼす第3のキナーゼ系Rhoキナーゼの役割について [PDF]

, 2004
　It has been known that various neurohumoral factors play important roles in the regulation of contraction and relaxation in cardiac muscle. Earlier reports suggested that angiotensin II play important roles in the pathogensis of chronic heart failure ...
茆原 るり
core  

Micro-RNAs of the miR-15 family modulate cardiomyocyte survival and cardiac repair [PDF]

, 2015
A family of microRNAs, called the miR-15 family, which includes miR-195, are shown to be up-regulated during pathological cardiac remodeling and repress the expression of mRNAs required for cell proliferation and survival, with consequent loss of ...
Olson, Eric N., van Rooij, Eva
core   +1 more source

One-year real-world experience with mavacamten and its physiologic effects on obstructive hypertrophic cardiomyopathy

Frontiers in Cardiovascular Medicine
Mavacamten is a first-in-class cardiac myosin ATPase inhibitor, approved by the United States Food and Drug Administration for the treatment of hypertrophic cardiomyopathy with obstructive physiology (oHCM).
Daniel Seung Kim, Daniel Seung Kim, Daniel Seung Kim, Daniel Seung Kim, Daniel Seung Kim, Emily L. Chu, Emily E. Keamy-Minor, Ishan Dhananjay Paranjpe, Wilson L. Tang, Jack W. O’Sullivan, Jack W. O’Sullivan, Jack W. O’Sullivan, Yaanik B. Desai, Yaanik B. Desai, Michael B. Liu, Michael B. Liu, Elise Munsey, Kimberly Hecker, Isabella Cuenco, Beth Kao, Ellen Bacolor, Colleen Bonnett, Andrea Linder, Kathleen Lacar, Nancy Robles, Cindy Lamendola, Allysonne Smith, Joshua W. Knowles, Joshua W. Knowles, Joshua W. Knowles, Joshua W. Knowles, Marco V. Perez, Marco V. Perez, Marco V. Perez, Marco V. Perez, Masataka Kawana, Masataka Kawana, Masataka Kawana, Karim I. Sallam, Karim I. Sallam, Karim I. Sallam, Chad S. Weldy, Chad S. Weldy, Chad S. Weldy, Matthew T. Wheeler, Matthew T. Wheeler, Matthew T. Wheeler, Matthew T. Wheeler, Victoria N. Parikh, Victoria N. Parikh, Victoria N. Parikh, Victoria N. Parikh, Heidi Salisbury, Euan A. Ashley, Euan A. Ashley, Euan A. Ashley, Euan A. Ashley, Euan A. Ashley, Euan A. Ashley, Euan A. Ashley, the Stanford Center for Inherited Cardiovascular Disease, Karim I Sallam, Masataka Kawana, Chad S Weldy, Marco Perez, Joshua W Knowles, Jason Tso, Cindy Lamendola, Allysonne Smith, Nancy Robles, Colleen Bonnett, Ellen Bacolor, Kimberly Hecker, Isabella Cuenco, Beth Kao, Elise Munsey, Andrea Linder, Kathleen Lacar, Julia Platt, Chloe Reuter, Tia Moscarello, Ryan Murtha, Jennifer Kohler, Hannah Ison, Mitchel Pariani, Anusha Klinder, Priya Nair, Jennifer Marino, Andrea Linder, Ruchi Patel, Matthew T Wheeler, Euan A Ashley, Victoria N Parikh   +92 more
doaj   +1 more source

Multi‐Omics Insights Into the Mechanisms of Early Muscle Fiber Difference and Transformation Between Lean‐Type and Chinese Indigenous Pigs

Advanced Science, EarlyView.
Multi‐omics analyses uncover breed‐specific cis‐regulatory landscapes and higher‐order chromatin architectural differences that underlie early postnatal muscle fiber divergence in pigs. A super‐enhancer upstream of PPP3CB recruits MEF2C to activate PPP3CB transcription, while the PPP3CB–MEF2C positive feedback loop promotes oxidative muscle fiber ...
Shuailong Zheng, Hainan Wu, Min Liu, Kunpeng Wu, Shuntao Huang, Zulfiqar Ahmed, Lenox Pius, Mengjin Zhu, Dequan Xu   +8 more
wiley   +1 more source

Rabbit models of heart disease. [PDF]

, 2008
Human heart disease is a major cause of death and disability. A variety of animal models of cardiac disease have been developed to better understand the etiology, cellular and molecular mechanisms of cardiac dysfunction and novel therapeutic strategies ...
Bers, Donald M, Pogwizd, Steven M
core